SL-01, formerly known as ZPCK, is an orally bioavailable analogue of gemcitabine that was synthesized by introducing the moiety of 3-(dodecyloxycarbonyl) pyrazine-2-carbonyl at N4-position on cytidine ring of gemcitabine. SL-01 inhibited human breast cancer growth through induction of apoptosis. SL-01 inhibited human cancer growth more potently than gemcitabine. References: Zhao C, Li Y, Qin Y, Wang R, Li G, Sun C, Qu X, Li W. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. Cancer Chemother Pharmacol. 2013 Jun;71(6):1541-50. doi: 10.1007/s00280-013-2153-6. Epub 2013 Apr 6. PubMed PMID: 23564376.

纯度：≥98%

CAS：26049-94-5